These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8639311)

  • 1. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group.
    Enblad G; Hagberg H; Glimelius B
    Acta Oncol; 1996; 35(2):165-70. PubMed ID: 8639311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group.
    Enblad G; Glimelius B; Hagberg H; Lindemalm C
    Acta Oncol; 1990; 29(3):297-301. PubMed ID: 2363941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study.
    Enblad G; Hagberg H; Gustavsson A; Glimelius B
    Eur J Haematol; 1998 Mar; 60(3):166-71. PubMed ID: 9548415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma.
    Hopfinger G; Heinz R; Koller E; Schneider B; Pittermann E
    Eur J Haematol; 1995 Oct; 55(4):223-7. PubMed ID: 7589338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
    Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study.
    Mirza MR; Brincker H
    Acta Oncol; 1991; 30(1):17-21. PubMed ID: 2009179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
    Cabanillas F; Velasquez WS; McLaughlin P; Jagannath S; Hagemeister FB; Redman JR; Swan F; Rodriguez MA
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):47-50. PubMed ID: 3041599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
    Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
    Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas.
    Nowrousian MR; Anders CH; Niederle N; Nagel-Hiemke M; Moritz T; Seeber S; Schmidt CG
    Ann Oncol; 1991 Jan; 2 Suppl 1():25-30. PubMed ID: 1710486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma].
    Li HH; Wu XX; Wang QS; Zhao Y; Bo J; Wang SH; DA WM; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):298-300. PubMed ID: 16638201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP.
    Verdonck LF; Dekker AW; de Gast GC; van Kempen ML; Lokhorst HM; Nieuwenhuis HK
    J Clin Oncol; 1992 Dec; 10(12):1949-54. PubMed ID: 1453209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VIM3-ARA C: an effective salvage regimen in refractory or recurrent aggressive non Hodgkin's lymphoma. A report on 18 cases.
    Dupriez B; Morel P; Fenaux P; Colcher-Plantier I; Facon T; Bauters F
    Hematol Oncol; 1991; 9(4-5):259-66. PubMed ID: 1743628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.